The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Open accessAbstract
Purpose: The role of systemic chemotherapy in the management of pancreatic endocrine carcinoma (islet cell carcinoma; PEC) is an area of considerable controversy. Response rates ranging from 6% to 69% have been reported for streptozocin-based chemotherapy. We retrospectively studied 84 patients with locally advanced or metastatic PEC who had been treated with fluorouracil, doxorubicin, and streptozocin (FAS) to determine the objective response rate, duration of progression-free survival (PFS), and duration of overall survival (OS). Patients and Methods: Eligible patients had histologic or cytologic confirmation of their tumor and measurable disease on computed tomography or magnetic resonance imaging scans. Response to treatment was evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee. Results: Sixty-one of the patients were male and 23 were female, with a median age of 54 years (range, 24 to 78 years). The response rate (RR) to FAS was 39%, with a median response duration of 9.3 months. The 2-year PFS rate was 41%, and the 2-year OS rate was 74%. The extent of liver metastatic disease correlated with a worse PFS (P = .01 by log-rank test) and a worse OS (P < .0001 by log-rank test). Analyses showed that metastatic replacement of more than 75% of the liver and prior chemotherapy were independently associated with inferior PFS. Conclusion: Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS. The volume of metastases in the liver is the most important predictor of outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032101 · Cited by 659
Hochwald, S. N., Zee, S., Conlon, K. C., Colleoni, R., Louie, O., Brennan, M. F., & Klimstra, D. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.030 · Cited by 397
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Yu, F., Venzon, D. J., Serrano, J., Goebel, S. U., Doppman, J. L., Gibril, F., & Jensen, R. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.615 · Cited by 341
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
Fj�llskog, M.-L. H., Granberg, D. P. K., Welin, S. L. V., Eriksson, C., �berg, K. E., Janson, E. T., & Eriksson, B. K. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1101::aid-cncr1426>3.0.co;2-v · Cited by 262
Cheng, P. N. M., & Saltz, L. B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990915)86:6<944::aid-cncr8>3.0.co;2-p · Cited by 199
Frank, M. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00146-x · Cited by 191
Eriksson, B., Skogseid, B., Lundqvist, G., Wide, L., Wilander, E., & Öberg, K. (1990) · Cancer · doi:10.1002/1097-0142(19900501)65:9<1883::aid-cncr2820650902>3.0.co;2-3 · Cited by 168
Hepatic Arterial Chemoembolization for Metastatic Neuroendocrine Tumors
Clouse, M. E., Perry, L., Stuart, K., & Stokes, K. R. (1994) · Digestion · doi:10.1159/000201208 · Cited by 167
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors
Bajetta, E., Rimassa, L., Carnaghi, C., Seregni, E., Ferrari, L., Bartolomeo, M. D., Regalia, E., Cassata, A., Procopio, G., & Mariani, L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980715)83:2<372::aid-cncr23>3.0.co;2-p · Cited by 165
Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
Perry, L. J., Stuart, K. E., Stokes, K. R., & Clouse, M. E. (1994) · PubMed · Cited by 135
Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors
Maton, P. N., Gardner, J. D., & Jensen, R. T. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536043 · Cited by 135
An Update of the Medical Treatment of Malignant Endocrine Pancreatic Tumors
Eriksson, B. K., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083913 · Cited by 135
Neuroendocrine Pancreatic Tumors Clinical Findings in a prospective study of 84 patients
Eriksson, B. K., Ouberg, K., & Skogseid, B. M. (1989) · Acta Oncologica · doi:10.3109/02841868909111209 · Cited by 128
Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors
Ruszniewski, P. B., & Malka, D. (2000) · Digestion · doi:10.1159/000051860 · Cited by 119
Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.
Sutliff, V. E., Doppman, J. L., Gibril, F., Venzon, D. J., Yu, F., Serrano, J., & Jensen, R. T. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2420 · Cited by 108
Pancreatic endocrine tumors: Recent advances
Jensen, R. T. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s170 · Cited by 95
Rivera, E., & Ajani, J. A. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199802000-00008 · Cited by 92
Self-citationFjällskog, M.-L., Sundin, A., Westlin, J. E., Öberg, K., Janson, E. T., & Eriksson, B. K. (2002) · Medical Oncology · doi:10.1385/mo:19:1:35 · Cited by 80
Saltz, L. B., Kemeny, N. E., Schwartz, G. K., & Kelsen, D. P. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3<958::aid-cncr2820740326>3.0.co;2-x · Cited by 61
Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin Analogues
Arnold, R., Frank, M. L., & Kajdan, U. (2009) · Digestion · doi:10.1159/000201211 · Cited by 60
Kaltsas, G., Mukherjee, J. J., Isidori, A. M., Kola, B., Plowman, P. N., Monson, J. P., Grossman, A. B., & BESSER, G. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01589.x · Cited by 47
Rougier, P., Oliveira, J., Ducreux, M. P., Théodore, C., Kac, J., & Droz, J. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90014-5 · Cited by 47
Bukowski, R. M., Tangen, C. M., Lee, R. S., Macdonald, J. S., Einstein, A. B., Peterson, R. F., & Fleming, T. R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1914 · Cited by 38
Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik, A. I., Tsai, S., Moattari, A. R., & Cheung, P. S. Y. (1988) · PubMed · Cited by 34
Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
Cited by
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Metadata
- Authors
- Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-12-01
- Volume
- 22
- Issue
- 23
- Pages
- 4762-4771
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162830031
- Cited by
- 607
- References
- 34
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.